‘Microprotein’ biotech Velia, backed by TCG and Foresite, to wind down
San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two years after a $55 million Series
San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two years after a $55 million Series
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million, roughly a week after WuXi AppTec also
Plus, news about General Proximity and PBS Biotech: I-Mab pauses CD73 development: The company is not moving forward with a program … Sign up to
The first biopharma venture fund to close in 2025 comes from industry veterans Joe Jimenez and Mark Fishman, two former Novartis leaders. Jimenez exclusively told
2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.